Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference

On August 29, 2018 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the event (Press release, Mirati, AUG 29, 2018, View Source [SID1234529138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Targeted Therapies Oncology – Aiming for the Bull’s Eye" Panel on Wednesday, September 5th at 3:15 p.m. ET/12:15 p.m. PT

"Landscape in Immuno-Oncology and Bi-Specific Antibodies" Panel on Thursday, September 6th at 9:00 a.m. ET/ 6:00 a.m. PT

The webcasts will be available through the "Investors" section of www.mirati.com, and a replay of the webcasts will be made available for 90 days following the event.

TRACON Pharmaceuticals To Present At 2018 Wells Fargo Healthcare Conference

On August 29, 2018 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, reported that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate update at the 2018 Wells Fargo Healthcare Conference at 9:05 pm EDT on Wednesday, September 5, 2018, at the Westin Waterfront in Boston, MA (Press release, Tracon Pharmaceuticals, AUG 29, 2018, View Source [SID1234529137]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events & Presentations" section within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018

On August 29, 2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on September 5, 2018, at 12:05pm ET at the St. Regis New York Hotel in New York City (Press release, ArQule, AUG 29, 2018, http://investors.arqule.com/news-releases/news-release-details/arqule-present-20th-annual-global-investment-conference [SID1234529136]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast of the presentation will be available via the "Investors & Media" section of ArQule’s website, www.arqule.com, under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation.

Fate Therapeutics to Present at Upcoming Investor Conferences

On August 29, 2018 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that Scott Wolchko, President and Chief Executive Officer, will present at two upcoming investor conferences in September (Press release, Fate Therapeutics, AUG 29, 2018, View Source [SID1234529135]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Wells Fargo Healthcare Conference at 3:00 p.m. ET on Wednesday, September 5, 2018 in Boston.

Morgan Stanley 16th Annual Global Healthcare Conference at 5:15 p.m. ET on Thursday, September 13, 2018 in New York City.

Live webcasts of the presentation will be available through the investor relations section of the Company’s website at www.fatetherapeutics.com. Following the live webcasts, an archived replay will be available on the Company’s website.

LIGAND TO PARTICIPATE IN H.C. WAINWRIGHT 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE

On August 29, 2018 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported that the company is scheduled to participate in H.C. Wainwright 20th Annual Global Investment Conference in New York City (Press release, Ligand, AUG 29, 2018, View Source [SID1234529134]). Presentation takes place on Wednesday, September 5, 2018 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time). John Higgins, CEO, and Matt Korenberg, CFO, will attend for Ligand.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on Ligand’s website at www.ligand.com. A replay of the presentation will be archived on the website for 30 days.